Shares of US protein-based vaccine maker Novavax closed down 19.4% at $10.15 yesterday having dropped as much as 24%, on the ...

A report of a case of motor neuropathy in a patient who received the vaccine last year has led the FDA to halt its ...

The report involved motor neuropathy in a participant of the phase 2 trial conducted outside the U.S., according to an Oct. 16 news release from the company. The participant received the vaccine in ...

Analyst Eric Joseph of J.P. Morgan maintained a Sell rating on Novavax (NVAX – Research Report), retaining the price target of $9.00.

The regulator placed a clinical hold on its Covid-19-influenza combination vaccine after one person reported nerve damage.

Shares of American pharmaceutical company Novavax (NVAX) fell 19% on reports that the U.S. Food and Drug Administration (FDA) ...

Standing desks may increase the risk of swollen veins and blood clots, a study in the International Journal of Epidemiology ...

NVAX's COVID-19-flu combination and stand-alone flu vaccines have been placed on hold after a study participant who took the ...

Dow, S&P 500, and Nasdaq futures are rising in premarket trading Thursday as the stock market reacts to Taiwan Semiconductor earnings in light of the recent ASML selloff.

The number of people with a medical bill on a credit report is down. But researchers found the decline was smaller in places ...

Novavax Inc.’s stock tumbled 16% early Wednesday after the company said the FDA has placed a clinical hold on its ...

Novavax said federal regulators put a clinical hold on its application for a combination Covid-19 and influenza vaccine and ...